Gossamer Bio Inc
GOSS2.100USD
+0.100+5.00%
交易中 （美東）報價延遲15分鐘
477.16M總市值
虧損本益比TTM
關於 Gossamer Bio Inc 公司
Gossamer Bio, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化用於治療肺動脈高壓 (PAH) 的色拉替尼。其候選產品色拉替尼，也稱爲 GB002，是一種研究性吸入式小分子血小板衍生生長因子受體 (PDGFR)、集落刺激因子 1 受體 (CSF1R) 和 c-KIT 抑制劑，正在 III 期臨牀試驗中評估其用於治療 PAH 的效果。與市場上銷售的三類 PAH 血管擴張療法相比，色拉替尼有可能通過解決 PAH 的潛在機制來逆轉病理重塑。吸入式色拉替尼旨在作用於 PDGFR、α 和 β 的兩種亞型以及 CSF1R 和 c-KIT 通路。除了 PAH 之外，色拉替尼還有望成爲治療與間質性肺病相關的肺動脈高壓 (PH-ILD) 的治療選擇。
公司簡介
公司代碼GOSS
公司名稱Gossamer Bio Inc
上市日期Feb 08, 2019
CEOMr. Faheem Hasnain
員工數量144
證券類型Ordinary Share
年結日Feb 08
公司地址3115 Merryfield Row
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92121
電話18586841300
網址https://www.gossamerbio.com/
公司代碼GOSS
上市日期Feb 08, 2019
CEOMr. Faheem Hasnain
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Christian Waage
Mr. Christian Waage
Executive Vice President - Technical Operations and Administration
Executive Vice President - Technical Operations and Administration
666.30K
+1.87%
Dr. Richard Aranda, M.D.
Dr. Richard Aranda, M.D.
Chief Medical Officer
Chief Medical Officer
205.95K
+5.92%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
120.29K
--
Ms. Caryn Peterson
Ms. Caryn Peterson
Executive Vice President - Regulatory Affairs
Executive Vice President - Regulatory Affairs
49.83K
--
Dr. Thomas O. (Tom) Daniel, M.D.
Dr. Thomas O. (Tom) Daniel, M.D.
Lead Independent Director
Lead Independent Director
38.09K
--
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
32.00K
--
Mr. Russell J. Cox
Mr. Russell J. Cox
Independent Director
Independent Director
7.20K
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert (Ob) Smith
Mr. Robert (Ob) Smith
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Steven D. Nathan, M.D.
Dr. Steven D. Nathan, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Christian Waage
Mr. Christian Waage
Executive Vice President - Technical Operations and Administration
Executive Vice President - Technical Operations and Administration
666.30K
+1.87%
Dr. Richard Aranda, M.D.
Dr. Richard Aranda, M.D.
Chief Medical Officer
Chief Medical Officer
205.95K
+5.92%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
120.29K
--
Ms. Caryn Peterson
Ms. Caryn Peterson
Executive Vice President - Regulatory Affairs
Executive Vice President - Regulatory Affairs
49.83K
--
Dr. Thomas O. (Tom) Daniel, M.D.
Dr. Thomas O. (Tom) Daniel, M.D.
Lead Independent Director
Lead Independent Director
38.09K
--
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
32.00K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Octagon Capital Advisors LP
8.07%
New Enterprise Associates (NEA)
7.96%
The Vanguard Group, Inc.
5.02%
ARCH Venture Partners
3.54%
Fidelity Management & Research Company LLC
3.34%
Other
72.06%
持股股東
持股股東
佔比
Octagon Capital Advisors LP
8.07%
New Enterprise Associates (NEA)
7.96%
The Vanguard Group, Inc.
5.02%
ARCH Venture Partners
3.54%
Fidelity Management & Research Company LLC
3.34%
Other
72.06%
股東類型
持股股東
佔比
Hedge Fund
30.00%
Investment Advisor
18.72%
Venture Capital
14.20%
Investment Advisor/Hedge Fund
12.33%
Corporation
2.76%
Research Firm
1.08%
Individual Investor
0.76%
Pension Fund
0.21%
Other
19.95%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
261
181.97M
80.06%
-60.13M
2025Q1
285
180.17M
79.28%
-64.51M
2024Q4
310
181.35M
80.03%
-59.94M
2024Q3
354
184.99M
81.77%
-80.44M
2024Q2
354
192.00M
84.87%
-65.92M
2024Q1
360
205.91M
94.29%
-56.87M
2023Q4
359
215.74M
99.04%
-22.98M
2023Q3
360
211.40M
97.17%
+97.02M
2023Q2
346
75.83M
79.45%
-49.80M
2023Q1
346
90.30M
97.95%
-52.80M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Octagon Capital Advisors LP
18.35M
8.07%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
18.09M
7.96%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
10.08M
4.44%
+49.73K
+0.50%
Mar 31, 2025
ARCH Venture Partners
8.06M
3.54%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
7.59M
3.34%
-340.02K
-4.29%
Mar 31, 2025
Acadian Asset Management LLC
6.36M
2.8%
+1.25M
+24.55%
Mar 31, 2025
SilverArc Capital Management, LLC
6.32M
2.78%
+148.84K
+2.41%
Mar 31, 2025
Palo Alto Investors LP
6.28M
2.76%
-200.00
-0.00%
Mar 31, 2025
Samsara BioCapital, LLC
6.13M
2.7%
--
--
Mar 31, 2025
683 Capital Management LLC
6.10M
2.68%
-875.00K
-12.54%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.19%
iShares Micro-Cap ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
ProShares Hedge Replication ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.19%
iShares Micro-Cap ETF
佔比0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0.02%
iShares Russell 2000 Growth ETF
佔比0.02%
ProShares Hedge Replication ETF
佔比0.01%
Schwab U.S. Small-Cap ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
